CJC-1295 No DAC / Modified GRF (1-29) (Research-Grade GHRH Analog)

For Laboratory Use Only – Not for Human or Veterinary Application

Product Overview

CJC-1295 No DAC, also referred to as Modified GRF (1-29), is a synthetic peptide analog of growth hormone-releasing hormone (GHRH), designed for research models requiring short-duration, pulsatile GH secretion. Unlike DAC-conjugated variants, this formulation maintains a short half-life, supporting experiments that aim to replicate physiological GH release patterns for precise time-series studies and receptor-response investigations.

This product is not approved for diagnostic, therapeutic, or clinical use.

Compound Details

Research Applications

CJC-1295 No DAC is used in laboratory models investigating:

• Pulsatile Growth Hormone Release Mapping
  • Studying GH secretion kinetics mimicking natural episodic release patterns
• Somatotropic Axis Investigation
  • Exploring hypothalamic-pituitary feedback mechanisms in time-series assays
• IGF-1 Response Dynamics
  • Researching IGF-1 modulation following acute GH exposure
• Protein Turnover and Musculoskeletal Models
  • Evaluating tissue remodeling and recovery pathways in preclinical assays
• Endocrine Regulation Studies
  • Assessing receptor desensitization during repeated administration protocols

The short half-life profile makes this compound suitable for experiments that require precise timing of GH elevation and return to baseline.

Mechanism of Action (Preclinical Models)

Modified GRF (1–29) selectively binds to GHRH receptors in the anterior pituitary, inducing an acute GH surge that mirrors physiological pulsatile release. Unlike its DAC-conjugated counterpart, this action allows for synchronization of GH pulses with experimental protocols and facilitates analysis of feedback and downstream effects with minimal prolonged activity.

Laboratory Use Profile

• Supports acute GH response modeling with short-acting kinetics
• Low risk of receptor desensitization under repeat administration
• Suitable for time-synchronized co-administration studies (e.g., with GHS or ghrelin receptor agonists)
• Compatible with multi-compound endocrine pathway assays

Handling Guidelines

• Reconstitute with sterile bacteriostatic water immediately before use
• Store reconstituted solutions at 2–8 °C
• Use within defined experimental protocols; discard unused portions per institutional guidelines
• Avoid repeated freeze-thaw cycles to maintain product integrity

Compliance Statement & Disclaimer

• Research Use Only: For use exclusively by qualified laboratory personnel
• Not FDA Approved: No therapeutic, diagnostic, or clinical claims are made
• Not for Human or Veterinary Use: Do not inject, ingest, or apply to humans or animals
• Qualified Handling: Must be handled following applicable institutional and regulatory guidelines

Quality Assurance

Manufactured under sterile, controlled laboratory conditions by HVY Research. Each batch undergoes rigorous testing for identity, purity, and consistency. All researchers must adhere to established laboratory safety standards, including the use of PPE.

View Lab Result

Disclaimer

This product is intended solely for scientific research purposes. It is not approved for therapeutic, diagnostic, or clinical use and is not for human or animal consumption. All information provided is for research and scientific reference only.